Key Considerations for the Individualizing Use of BTK Inhibitors in B-Cell Malignancies

Experts review guideline recommendations for the use of BTK inhibitors for the management of CLL/SLL and MCL, the selection of BTK inhibitors based on patient characteristics, and key adverse events.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Partners for Advancing Clinical Education (PACE)

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca